Metraipolis › archive › dc_379c8608fa50

Repurposing approved drugs as Pendrin (SLC26A4) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation — Europe PMC PMID:42812201

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42812201
DOI
10.3389/fphar.2026.1926844
License (as archived)
solo-consultazione
Archived
2026-10-08T13:11:48.926Z
SHA-256 of the archived text
7880b749a3722d50548fcbfa770a1c22718a795ef55e2ebee6b41ca922d1be60
Stable URL of this page
https://metraipolis.com/documento/dc_379c8608fa50

How to cite

Repurposing approved drugs as Pendrin (SLC26A4) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation — Europe PMC PMID:42812201 — Europe PMC (en), https://europepmc.org/article/MED/42812201 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_379c8608fa50 (Metraipolis archive dc_379c8608fa50, sha256 7880b749a3722d50548fcbfa770a1c22718a795ef55e2ebee6b41ca922d1be60)
BibTeX
@misc{dc379c8608fa50,
  title = {Repurposing approved drugs as Pendrin (SLC26A4) inhibitors in allergic asthma: single-cell nomination, structure-based screening and functional validation — Europe PMC PMID:42812201},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42812201},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_379c8608fa50; sha256 7880b749a3722d50548fcbfa770a1c22718a795ef55e2ebee6b41ca922d1be60},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42812201. Agents can read the archived copy with the MCP tool read_document.